<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363376</url>
  </required_header>
  <id_info>
    <org_study_id>06-06-14-01</org_study_id>
    <secondary_id>F1D-MC-X269</secondary_id>
    <nct_id>NCT00363376</nct_id>
  </id_info>
  <brief_title>A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lindner Center of HOPE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lindner Center of HOPE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this study is to evaluate the efficacy, tolerability, and safety of&#xD;
      zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for&#xD;
      psychotic or bipolar disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, 16-week, randomized, double-blind, placebo-controlled, parallel&#xD;
      group, flexible-dose study in 60 outpatients with schizophrenia, schizoaffective disorder,&#xD;
      schizophreniform disorder, delusional disorder, psychotic disorder NOS, or bipolar disorder&#xD;
      types I, II, or NOS by DSM-IV-TR criteria43 with a BMI &gt; 22 for whom treatment with&#xD;
      olanzapine (5-20 mg/day) would be appropriate as monotherapy or adjunctive therapy. Subjects&#xD;
      who meet entry criteria will be randomized to treatment with olanzapine plus zonisamide or&#xD;
      olanzapine plus placebo. All subjects will receive Personal Wellness Solution Counseling&#xD;
      (http://www.zyprexa.com/hcp/hcp_patient_c_solutions_print.jsp). Both before and after&#xD;
      randomization to zonisamide or placebo, patients will not be permitted to have any other&#xD;
      major psychotropic medications (antipsychotics, mood stabilizers, antidepressants, or&#xD;
      anxiolytics) added to their medication regimens. The primary outcome measure will be change&#xD;
      in weight. Secondary outcome measures will include the Young Mania Rating Scale (YMRS),44 the&#xD;
      Inventory for Depressive Symptoms (IDS),45 the Positive and Negative Symptoms Scale&#xD;
      (PANSS),46 the Clinician Global Improvement (CGI) scale,47 the Binge Eating Scale (BES) 48,&#xD;
      BMI, waist circumference, and metabolic variables (fasting lipids, glucose, insulin).&#xD;
&#xD;
      Subjects will be inpatients or outpatients at the time of randomization to&#xD;
      olanzapine-zonisamide or olanzapine-placebo. Throughout the study, psychiatric scales will be&#xD;
      used to assess psychiatric symptoms, and the presence of treatment-emergent adverse events&#xD;
      will be monitored and recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in weight from baseline to endpoint</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in BMI</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in abdominal circumference</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in metabolic parameters</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in clinical global improvement of psychiatric symptoms</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in manic symptoms</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in depressive symptoms</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes, from baseline to endpoint, in psychotic symptoms</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine and placebo (&quot;sugar pill&quot;)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine and zonisamide (active drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zonisamide</intervention_name>
    <description>Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_label>Zonisamide</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_label>Zonisamide</arm_group_label>
    <other_name>Zyprexa</other_name>
    <other_name>Zydis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>zonisamide ranging from 100mg to 600mg daily</description>
    <arm_group_label>Zonisamide</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill (placebo)</intervention_name>
    <description>sugar pill (placebo) for zonisamide</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria for entering this study will include all of the following:&#xD;
&#xD;
          1. Subjects must be 18 years of age or older.&#xD;
&#xD;
          2. Subjects must have schizophrenia, schizoaffective disorder, schizophreniform disorder,&#xD;
             delusional disorder, psychotic disorder NOS, or bipolar I, II, or NOS disorder as&#xD;
             defined by DSM-IV-TR criteria.&#xD;
&#xD;
          3. Subjects must have a BMI &gt; 22.&#xD;
&#xD;
          4. Subjects must sign the Informed Consent Document after the nature of the trial has&#xD;
             been fully explained.&#xD;
&#xD;
          5. If female, subjects must be: postmenopausal, surgically incapable of childbearing, or&#xD;
             practicing medically acceptable effective method(s) of contraception (e.g., hormonal&#xD;
             methods, intrauterine device) for at least one month prior to study entry and&#xD;
             throughout the study.&#xD;
&#xD;
          6. If exposed to olanzapine in the past, subjects must be free of olanzapine for &gt; 3&#xD;
             months prior to randomization to study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria for exclusion from this study will be any of the following:&#xD;
&#xD;
          1. Subjects with clinically significant suicidal or homicidal ideation.&#xD;
&#xD;
          2. Subjects with a current DSM-IV Axis I diagnosis of delirium, dementia, amnesia, or&#xD;
             other cognitive disorders; a psychotic or mood disorder secondary to substance use or&#xD;
             a general medical disorder; or a DSM-IV diagnosis of a substance use disorder within&#xD;
             the past six months.&#xD;
&#xD;
          3. Cardiovascular, endocrine, neurologic, or hematologic disease as determined by the&#xD;
             clinical judgment of the clinical investigator. Subjects with hypo- or hyperthyroidism&#xD;
             unless stabilized on thyroid replacement &gt; 3 months.&#xD;
&#xD;
          4. Subjects who are allergic to or who have demonstrated hypersensitivity to or&#xD;
             significant adverse event from olanzapine.&#xD;
&#xD;
          5. Subjects who are allergic to or who have demonstrated hypersensitivity to zonisamide.&#xD;
&#xD;
          6. Women who are pregnant or nursing.&#xD;
&#xD;
          7. Subjects who have received an experimental drug or used an experimental device within&#xD;
             30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan McElroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Lindner Center of HOPE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Lindner Center of HOPE</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McElroy SL, Winstanley E, Mori N, Martens B, McCoy J, Moeller D, Guerdjikova AI, Keck PE Jr. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012 Apr;32(2):165-72. doi: 10.1097/JCP.0b013e3182488758.</citation>
    <PMID>22367654</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>olanzapine</keyword>
  <keyword>zonisamide</keyword>
  <keyword>weight gain</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>psychotic disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

